SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

PMCB RSS Feed
Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator bulldurham, TraderpennyX, Peacefulwendy, TheBestInvest, $Pistol Pete$
Search This Board:
Last Post: 5/29/2015 12:34:15 AM - Followers: 535 - Board type: Free - Posts Today: 1

Welcome to PharmaCyte BioTech
FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment

http://www.nuvilex.com/latest-news/149-fda-grants-orphan-drug-designation-to-nuvilex-for-pancreatic-cancer-treatment








Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious:
Data from Two Clinical Trials in Pancreatic Cancer

http://www.mdpi.com/1999-4923/6/3/447




















ThaiTECT ???????? 14 - Drug Development Part I : International Experiences

http://www.youtube.com/watch?v=nL_LznwTdKk


Nuvilex/Austrianova declared the winner of the 2014 Best Innovation Award
 
http://client.irwebkit.com/Nuvilex/news/2433458






Encapsulation of Insulin Producing Cells for Diabetes Treatment Using 
Alginate and Cellulose Sulphate as Bioencapsulation Polymers


http://austrianova.com/wp-content/uploads/2014/09/DRTOA-1-102-final.compressed.pdf


NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)

                                            

PharmaCyte Company Address
   PharmaCyte BioTech, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851
   email:
 info@pharmacytebiotech.com


Market Value:
$76,201,902 a/o Mar 11, 2015

Shares Outstanding:
699,292.029 a/o Dec 15, 2014

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

Float:
529,206,849 a/o Aug 26, 2014


Short Selling Data

Short Interest: 363,107 (1.685) a/o Feb 13, 2015

For more updated information please visit: 


http://www.otcmarkets.com/stock/PMCB/profile


Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations


Jamien Jones 
Blueprint Life Science Group 
Telephone: 415.375.3340 Ext. 103 
jjones@bplifescience.com 

http://bplifescience.com/clients.html 

                                               

All News Releases: 
http://www.nuvilex.com/latest-news

All Information about Nuvilex:
http://www.stockmarketmediagroup.com/features/nvlx/

What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans.


http://austrianova.com/products/ 



PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.



">

Austria Nova Demonstration Video

 
 

SMMG Radio Interview with COO Dr. Crabtree ~ 2013





Shareholder Update with CEO & COO via SMMG Interview ~ July 2014






The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool


Management Team:

 

Kenneth L. Waggoner, Chief Executive Officer and President:


Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.

 

Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:



Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Walter H. Gunzburg – Chief Scientific Officer:



Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. He was a scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001 and was involved in their IPO. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc., all of which developed/are developing advanced medicinal treatments for cancer. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.

Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years. He was a member of the German Medical Association's Central Commission for Somatic Gene Therapy. He has also interacted with a number of regulatory agencies including the US FDA, EMA, TGA, HSA and Thai-FDA and was on the review panel for the Paul Ehrlich Institute, Langen, Germany. Prof. Gunzburg continues to be an active researcher and has published more than 130 peer-reviewed publications in international scientific and medical journals such as NatureThe Lancet,Proceedings of the National Academy of Sciences USA and Cancer Research as well as co-authoring the first German language textbook on gene therapy. He is also a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine, and continues to be an active reviewer for many top tier journals as well as grant funding agencies.


Dr. Matthias Lohr as Chairman of Scientific Advisory Board:



Matthias Löhr was appointed professor of gastroenterology & hepatology at Karolinska Institutet in 2007, incoming from the Univ. Heidelberg/dkfz. From the times of his MD thesis through PhD and lateron, he concentrated on several aspects of the pancreas, both in clinical medicine, translational and basic sciences. He is heading the Pancreas Research Team at Gastrocentrum and leading the KICancer Diagnose-related network for HPB tumors. For hte European Gastroenterologists (UEG), he is sitting in several committees at the EU in Brussels. He is also leading the Pancreas 2000 program, an educational program for future pancreatologists in Europe.

Thomas Liquard - Chairman of the Audit Committe


Mr. Liquard is a seasoned pharmaceutical industry executive whose past experiences include serving as Chief Executive of Alchemia Limited and as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio for Pfizer in New York.

 

Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development




 

Following receipt of her Doctorate in Natural Sciences in the areas of Biochemical Microbiology and Molecular Genetics in 2001, Dr. Brandtner served as a Postdoctoral Scientist and Senior Postdoctoral Fellow at Austrianova Biomanufacturing AG in Austria where she was involved in the development of retroviral vectors for gene therapy.  In 2007, Dr. Brandtner moved to Singapore and became Project Manager for work on the cell-based therapy of liver cancer at the same company.  Shortly thereafter, Dr. Brandtner was promoted to Senior Scientist at Austrianova Pte Ltd (Austrianova) where she oversaw the development of numerous projects concerned with live cell Bioencapsulation.  This was followed in 2010 by her promotion to Chief Scientist at Austrianova, responsible for all encapsulation projects in medicine and biology.  Most importantly, while at Austrianova, Dr. Brandtner was intimately involved in all of the preclinical work done there that included the use of live cell encapsulation in developing a treatment for insulin-dependent diabetes.  Due to family commitments, in 2012 Dr. Brandtner left Singapore to return to Austria where she is currently employed as Head of the Bioencapsulation Unit at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT).

Dr. Brandtner is co-inventor on two granted patents and is named on several additional patents that are in preparation.  She has co-authored numerous research reports that have been published in reputable scientific journals and has presented research results at national and international scientific conferences and meetings.  Dr. Brandtner is a member of the European Association for the Study of Diabetes (EASD), the Austrian Diabetes Association (ÖDG) and the European Society for Gene and Cell Therapy (ESGCT).



 

 



Stock Chart http://www.otcmarkets.com/stock/NVLX/chart
Company Info http://www.otcmarkets.com/stock/NVLX/company-info
Recent News http://www.otcmarkets.com/stock/NVLX/news
Financials http://www.otcmarkets.com/stock/NVLX/financials
Filings and Disclosure http://www.otcmarkets.com/stock/NVLX/filings
Short Sales http://www.otcmarkets.com/stock/NVLX/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/NVLX/insider-transactions
Research Reports http://www.otcmarkets.com/stock/NVLX/research
Summary http://finance.yahoo.com/q?s=NVLX
Historical Prices http://finance.yahoo.com/q/hp?s=NVLX+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=NVLX
Basic Chart http://finance.yahoo.com/q/bc?s=NVLX+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=NVLX+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=NVLX+Headlines
Press Releases http://finance.yahoo.com/q/p?s=NVLX+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=NVLX+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=NVLX+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=NVLX+Industry
Major Holders http://finance.yahoo.com/q/mh?s=NVLX+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=NVLX+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=NVLX+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=NVLX
Balance Sheet http://finance.yahoo.com/q/bs?s=NVLX
Cash Flow http://finance.yahoo.com/q/cf?s=NVLX+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/NVLX
Market Watch http://www.marketwatch.com/investing/stock/NVLX
Bloomberg http://www.bloomberg.com/quote/NVLX:US
Morningstar http://quotes.morningstar.com/stock/s?t=NVLX
Bussinessweek http://investing.businessweek.com/research/st...icker=NVLX
Barchart http://www.barchart.com/quotes/stocks/NVLX
OTC Short Report http://otcshortreport.com/index.php?index=NVLX
Investopedia http://www.investopedia.com/markets/stocks/NVLX/?wa=0

Features http://www.stockmarketmediagroup.com/features/nvlx/

 

                                  

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PMCB
Current Price
Volume:
Bid Ask Day's Range
Wiki
NVLX News: Current Report Filing (8-k) 01/09/2015 11:34:14 AM
NVLX News: Nuvilex Announces Name Change to PharmaCyte Biotech 01/07/2015 09:30:00 AM
NVLX News: Nuvilex to Attend 2015 Gastrointestinal Cancers Symposium in San Francisco, January 15-17, 2015 01/06/2015 09:30:00 AM
NVLX News: FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment 12/22/2014 08:30:00 AM
NVLX News: Nuvilex’s Partner Austrianova Successfully Completes First Live-Cell Encapsulation in New Facility 12/18/2014 09:30:00 AM
PostSubject
#35982  Sticky Note $PMCB New Advances in Diabetes Treatment: Insulin-Produc $Pistol Pete$ 05/21/15 10:05:20 AM
#35970  Sticky Note Great interview with Dr Crabtree. Really good Peacefulwendy 05/20/15 09:01:54 PM
#33559  Sticky Note PharmaCyte Biotech Inc. >>> Insulin / Type 1 TraderpennyX 04/01/15 06:31:41 AM
#31958  Sticky Note PharmaCyte Biotech Initiates Expanded Follow-up Study in the bulldurham 02/19/15 09:31:41 AM
#31423  Sticky Note PharmaCyte Biotech Initiates First Preclinical Study of Its TheBestInvest 02/04/15 11:38:18 AM
#18112  Sticky Note EVERYONE please keep your posts on-topic. The topic IH Geek [Dave] 03/14/14 12:28:20 PM
#36111   $PMCB charts $Pistol Pete$ 05/29/15 12:34:15 AM
#36110   Thanks for the analysis, Pete... Peacefulwendy 05/28/15 04:38:50 PM
#36109   $PMCB $PMCB hourly chart still trending. She $Pistol Pete$ 05/28/15 04:07:52 PM
#36108   Yeah...looks like WDCO tried to cover for the $Pistol Pete$ 05/28/15 03:45:46 PM
#36107   Looks like the mm don't want pps to Gmc2020 05/28/15 03:32:22 PM
#36106   $PMCB WDCO market maker tried to manipulate PPS $Pistol Pete$ 05/28/15 01:07:52 PM
#36105   Thanks Mick... Peacefulwendy 05/28/15 11:07:11 AM
#36104   Cool, we are all on the same page. BioNewton 05/28/15 10:50:29 AM
#36103   Pharmacyte Biotech, (PMCB) mick 05/28/15 10:05:01 AM
#36102   in your asking, i will have ah chart mick 05/28/15 10:03:37 AM
#36101   8k out. New high powered accounting firm JDT188 05/28/15 08:10:05 AM
#36100   Fantastic Sentiments mate! The Promised Land 05/28/15 03:33:55 AM
#36099   Can someone provide a chart analysis? I Peacefulwendy 05/27/15 11:51:25 PM
#36097   Son? Based on the maturity of your attack, MOangler 05/27/15 11:02:01 PM
#36096   Thanks Bio, sometimes just got to cut MOangler 05/27/15 11:00:14 PM
#36091   Peacefulwendy...once again you are spot on....eom efood125 05/27/15 07:06:41 PM
#36090   'PharmaCyte Biotech Inc. (PMCB)' mick 05/27/15 06:01:23 PM
#36089   Sounds like all good news. PiieTwo 05/27/15 05:44:28 PM
#36088   There name is already out in the community. Also PiieTwo 05/27/15 05:42:51 PM
#36087   The only way to raise funds is through LuCo 05/27/15 05:37:41 PM
#36086   It's a diversion tactic. If someone can Peacefulwendy 05/27/15 05:24:06 PM
#36085   i agree/ Pharmacyte Biotech, (PMCB) mick 05/27/15 04:53:18 PM
#36084   $PMCB chart for you and nice closed today stockcharts.com/c-sc/sc?s=PMCB $Pistol Pete$ 05/27/15 04:51:04 PM
#36083   Well said. Life is life and fun trently 05/27/15 04:06:10 PM
#36082   $PMCB PharmaCyte Biotech Takes a Cancer-Treatment Quantu $Pistol Pete$ 05/27/15 03:40:17 PM
#36080   No Scams here at all, just look at The Promised Land 05/27/15 01:44:58 PM
#36079   PMCB is a penny stock, only way to dealerschool2006 05/27/15 01:20:31 PM
#36078   If you have free spare time. Please listen $Pistol Pete$ 05/27/15 12:28:32 PM
#36077   PMCB's only product is to sell shares. Alydyr 05/27/15 12:28:27 PM
#36076   Speaking of trying to fool people. You BioNewton 05/27/15 12:23:47 PM
#36075   Liabilities, accumulated deficit and stockholder's equity are all Alydyr 05/27/15 12:09:31 PM
#36074   I'm sure the $77 Million deficit will be BioNewton 05/27/15 12:03:23 PM
#36073   Von Hoff still on the golf course? Alydyr 05/27/15 11:57:05 AM
#36072   Q & A with our CEO on our Peacefulwendy 05/27/15 11:48:54 AM
#36071   Dr Crabtree in a radio interview sharing Cell Peacefulwendy 05/27/15 11:44:48 AM
#36070   The only product I see here at PMCB Alydyr 05/27/15 11:24:30 AM
#36069   Wait!!! A company with no product on BioNewton 05/27/15 11:20:32 AM
#36068   Validity of over $77 MILLION in accumulated losses here. Alydyr 05/27/15 11:07:36 AM
#36067   Wow, third parties are cutting and pasting PMCB BioNewton 05/27/15 11:01:46 AM
#36066   I can't help but wonder if ths attendance iwitness4jc 05/27/15 10:51:10 AM
#36065   Compensation: We expect to receive five thousand dollars Alydyr 05/27/15 10:46:05 AM
#36064   Not pumping -- just more pieces of the BioNewton 05/27/15 10:03:29 AM
#36063   Exactly Wendy. The truth is that we are avobill 05/27/15 09:10:21 AM
#36062   LuCo, I don't see this as "big news" either. avobill 05/27/15 09:06:19 AM
#36061   Pharmacyte Biotech, (PMCB) mick 05/26/15 10:04:44 PM
#36060   Thanks Pistol Pete, It will be a nice Galactic Green 33 05/26/15 09:43:57 PM
#36059   Excellent post JDT188. It is not smart to $Pistol Pete$ 05/26/15 09:37:08 PM
#36058   Welcome to $PMCB board Galactic Green 33. Enjoy $Pistol Pete$ 05/26/15 09:30:27 PM
#36057   Nice PR $PMCB. Picked up some shares today, Galactic Green 33 05/26/15 08:40:46 PM
#36056   JDT188 Hit it right on the nose! Its Havana11 05/26/15 08:23:59 PM
PostSubject